- Sarah Millard, Medically reviewed by Luke Wright, PharmD
- Jul 20
- 5 min read
Updated: 4 minutes ago
From peptide science to patient care
What the PCAC review reveals about the research, regulation, and future of peptide therapeutics.
Highlights
Decades of research continue to expand what we know about peptide biology.
PCAC is evaluating whether seven peptide families meet the criteria for the 503A Bulks List - not whether peptide science is valid.
Regulated healthcare and pharmacy channels include sourcing, quality, testing, and oversight that gray market products and facilities may not provide.
Peptide medicine advances when scientific research, clinical expertise, and pharmacy practice work together.
In our first peptide article, we explored why peptides are uniquely suited to personalized medicine. Now, an upcoming meeting of the Pharmacy Compounding Advisory Committee (PCAC) is bringing a new group of peptides into discussion. The July meeting is important, but it represents only one part of a much larger story.
The peptide evolution
Peptide medicine did not begin with today's wellness conversations. Researchers have devoted their time, energy, and life's work studying how short chains of amino acids influence inflammation, tissue repair, neurological signaling, metabolic regulation, and many other biological processes.
Scientific evidence is not created in a single moment. It develops across a continuum, with each stage answering a different question.
Foundational research
Identifies peptide structure, biological origin, signaling pathways, and cellular activity.
Preclinical research
Examines biological effects in laboratory and animal models, helping researchers understand mechanisms, dose response, pharmacology, and potential applications.
Translational research
Builds the bridge between biological findings and potential human use, including formulation, delivery, stability, biomarkers, and pharmacokinetics.
Clinical research and practice
Studies human outcomes and helps providers apply evidence within the context of medical history, treatment goals, response, tolerability, and clinical judgment.
Peptide science develops differently from the commercial drug development pathway. A molecule may have decades of research behind it without having a pharmaceutical sponsor willing to finance the large clinical development program required for an FDA-approved product. The absence of that commercial pathway should not be confused with the absence of scientific research.
FDA regulatory tension
In April 2026, the FDA removed seven peptide families from its Category 2 substances list and formally published a notice in the Federal Register announcing that PCAC would meet on July 23 and 24 to discuss recommendations for the seven removed peptides. PCAC will make their non-binding recommendations at the July meeting, and the FDA will review before deciding next steps. Even a positive PCAC recommendation does not guarantee a substance will be placed in Category 1 or ultimately added to the 503A Bulks List.
Compounding and the FDA
So, what is happening between compounding pharmacies and the FDA? The regulatory tension can be better understood as a mismatch of models, not a battle between "safe FDA drugs" and "unproven compounded drugs."
The FDA approval framework is designed primarily around standardized, mass-manufactured drug products, while 503A compounding addresses patient-specific needs through the practice of pharmacy.
The PCAC panel brings together physicians, pharmacists, clinical researchers, and experts with experience in compounding and related areas of medicine. Their role is to evaluate whether specific substances meet the statutory criteria for the 503A Bulks List - not whether peptide science is legitimate or whether decades of foundational research have value.
Peptides under review
The peptides up for discussion are supported by varying bodies of biochemical, cellular, animal, translational, and human research. The July meeting provides an opportunity to examine that science, understand what each peptide is being studied to do, and explore how research moves responsibly from the laboratory into personalized clinical care.
BPC-157
Researchers affiliated with the University of Cambridge, Johns Hopkins University, and other medical and academic institutions have explored BPC-157's potential role in gastrointestinal tissue protection, muscle and bone repair, vascular and microcirculatory support, inflammation regulation, and pain-related signaling. Human research has also been reported, including pilot investigations involving musculoskeletal discomfort and interstitial cystitis.
TB-500
Researchers affiliated with the Korea Institute of Science and Technology and the University of Science and Technology in Seoul have studied TB-500's metabolism and its potential role in fibroblast migration, wound healing processes, angiogenesis, connective-tissue recovery, and inflammatory regulation. A 2024 laboratory study identified several TB-500 metabolites and found that one significantly increased fibroblast wound closure, suggesting that both the peptide and the smaller sequences produced during metabolism may contribute to its biological activity.
MOTS-c
Researchers at the USC School of Gerontology, UCLA, the National Institute on Aging, and other institutions have studied MOTS-c's role in mitochondrial signaling, glucose utilization, insulin sensitivity, exercise adaptation, physical performance, and age-related metabolic change. Animal studies found that MOTS-c improved metabolic function.
KPV
Researchers at Emory University School of Medicine and other institutions have studied KPV's potential role in intestinal inflammation, epithelial barrier support, wound healing, and immune regulation. Preclinical research suggests that KPV can enter intestinal and immune cells through the PepT1 transporter and influence inflammatory pathways, while later studies have explored targeted delivery systems designed to bring the peptide directly to affected tissue.
Emideltide (DSIP)
Researchers at the University of Amsterdam and across other European institutions have investigated emideltide's potential role in sleep regulation, neuroendocrine signaling, pain, stress adaptation, and physiological responses to withdrawal. A small double-blind study involving patients with chronic insomnia reported improvements in sleep latency and efficiency.
Semax
Neuroscience institutions have explored Semax's potential role in neuroprotection, neuroplasticity, inflammatory regulation, oxidative stress, and neurological recovery. In addition to extensive preclinical research, human studies involving ischemic stroke have reported improvements in functional and motor recovery when Semax was used alongside early rehabilitation.
Epitalon
Researchers at European institutions have studied Epitalon's potential influence on telomerase activity, telomerase maintenance, circadian signaling, melatonin regulation, oxidative stress, and cellular aging pathways. Experimental and early clinical research has examined sleep-related physiology, retinal function, and age-associated biological changes.
From peptide science to clinical care
Scientific research and clinical practice do not compete with one another. Research identifies mechanisms, tests hypotheses, and expands what is biologically possible. Providers bring that knowledge into the context of an individual patient. Compounding pharmacists help translate a prescription into a patient-specific preparation using appropriate ingredients, formulation methods, and quality controls.
Peptide medicine sits at the intersection of all three. Its continued development will depend on researchers, prescribers, and pharmacists understanding the role each plays and remaining willing to learn from one another. None replace the others.
The gray market
The July review is not the end of the process. The FDA also announced that PCAC will meet before the end of February 2027 to consider five additional substances: cathelicidin (LL-37), GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF.
These actions bring a broader patient-safety problem into clearer view. Demand for these substances has moved towards gray market products sold outside of regulated healthcare and pharmacy channels, often without transparent quality, sourcing, sterility, potency, or testing standards, and operating outside of safeguards intended to protect patients. Providers should be cautious of pharmacies already promoting or compounding these peptides before upcoming regulatory decisions have been made.
Where do we go from here
The PCAC recommendations and potential FDA approvals determine whether a substance may legally be used under the compounding framework, but a compounding pharmacy's evaluation does not need to stop at regulatory eligibility.
The evaluation should include the published literature, proposed clinical application, ingredient identity and sourcing, formulation feasibility, route of administration, stability, sterility, and testing requirements.
There is substantial science here. The evidence is developing. Regulation is evolving. Your compounding pharmacy should understand all three, with the focus on thoughtful formulation decisions, responsible sourcing, quality, and patient need - not trend chasing.